Introduction
Crohn's disease [CD] is an immunologically mediated chronic disease characterised by episodic intestinal inflammation and dysregulation of the mucosa-associated immune system. 1 Anti-inflammatory and immunosuppressive agents are the mainstay of therapy, but up to 25% of patients remain refractory to optimal medical therapy, and a further 50% experience loss of response. 2, 3 Treatment-refractory CD is associated with adverse quality of life, recurrent hospitalisation, and increased mortality. 4, 5 Autologous haematopoietic stem cell transplantation [AHSCT] is a potential therapeutic option for treatment-refractory CD. 6 AHSCT may lead to remission in CD by chemotherapy-mediated ablation of inflammatory cells followed by marrow reconstitution and restoration of immune tolerance. 7 The mechanisms underlying this process are incompletely defined, but thymic re-activation, broadening of the total T, B, NK cell, and plasma cell repertoire, and resetting of regulatory T cell function, have been suggested to play a role. 8 Clinical experience of AHSCT for CD is limited, with several small series suggesting clinical benefits. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] In a Phase 1/2 study of 24 patients with severe treatment-refractory CD, AHSCT resulted in clinical relapse-free survival of 91% at 1 year and 19% at 5 years, with a rapid and sustained improvement in Crohn's Disease Activity Index [CDAI] post AHSCT. 10 Only one randomised trial of AHSCT for CD [ASTIC] has been reported to date. 19 This study enrolled patients with active CD not amenable to surgery and unresponsive to treatment with three or more immunosuppressive/biologic agents to AHSCT [n = 23] or control [mobilisation and AHSCT deferred for 1 year, n = 22]. One patient died of sepsis and hepatic venoocclusive disease, and the trial failed to meet its primary endpoint of clinical and endoscopic 'cure' at 1 year, a composite of freedom from disease on imaging and endoscopy, CDAI < 150 and no active treatment for 3 months. This has been criticised for being overly stringent, and patients demonstrated sustained improvement on prespecified secondary endpoints. 19, 20 European Society for Blood and Marrow Transplantation [EBMT] guidelines, published in 2012, have included recommendations for AHSCT in CD types: i] active and unresponsive disease despite multiple lines of therapy; ii] extensive disease where surgical resection would expose the patient to small bowel syndrome risk; and iii] refractory colonic disease where a stoma is not acceptable to the patient. 6 As the number of patients undergoing AHSCT in any centre to date are limited, multicentre studies are required. EBMT maintains a registry of all patients undergoing AHSCT for any indication, and provides a means to identify the total European cohort. We therefore designed this retrospective study to evaluate the clinical use and outcomes of all AHSCT in CD performed in EBMT transplant centres outside the ASTIC trial.
Methods

EBMT registry
EBMT is a not-for-profit medical and scientific organisation that represents over 500 HSCT centres from over 50 countries. The EBMT registry now contains details on over 500 000 allogeneic and autologous transplants performed since 1986. All patients included in the registry give written consent before transplant for the collection and analysis of anonymised data. The data are maintained in the central EBMT registry in line with legal and regulatory requirements for data protection, confidentiality, and accuracy. EBMT implements regular quality assurance measures including ensuring centre accreditation, regular cross-checks with national registries, annual surveys, and regular audit processes. This study was performed in line with EBMT guidelines and approved by the Autoimmune Diseases Working Party [ADWP].
Patient population
Patients who underwent AHSCT for Crohn's disease were identified from the EBMT registry. All adult patients [aged ≥18 years at time of AHSCT] undergoing AHSCT for a primary diagnosis of CD from 1997 to 2015 were eligible for inclusion. Patients who had participated in the ASTIC trial were excluded. From a total of 99 patients across 27 centres, data were obtained for 82 patients transplanted in 19 centres in eight countries from 1996 to 2015[see Supplementary data available at ECCO-JCC online]. Data were unavailable for 17 patients due to lack of response to repeated requests. 
Study endpoints
Definitions
Clinical disease response was categorised as:
• remission: no abdominal pain and normal stool frequency; • improvement: improvement in abdominal pain and/or stool frequency; • stable/no change: no appreciable improvement in abdominal pain and/or stool frequency; • worse: deterioration in abdominal pain and/or stool frequency.
The introduction, reduction, or withdrawal of steroids, immunomodulators, or biologic therapy, and need for further surgical therapy, were also recorded.
Disease behaviour was assessed as stricturing, penetrating, both, or neither, pre-and post-AHSCT [Supplementary Table 2, available as Supplementary data at ECCO-JCC online]. Neutrophil engraftment was defined as time from day of transplant until Day 1 of 3 consecutive days with an absolute neutrophil count ≥0.5 x 10^9/L, whereas platelet engraftment was defined as time from day of transplant until Day 1 of 3 consecutive days with a platelet count ≥20 x 10^9/L. Treatment-related mortality [TRM] was defined as any death after AHSCT within the first 100 days post-AHSCT. Treatment-free survival was defined as survival from transplantation without major surgery or medical therapy.
Statistics
Qualitative variables were described as percentage, continuous variables using median and range. Overall survival and treatment-free survival were calculated according to the method of Kaplan and 
Results
Patient and disease characteristics
Patient and disease characteristics are summarised in Table 1 
AHSCT characteristics and haematological outcomes
AHSCT details are summarised in Table 3 . All patients underwent mobilisation with cyclophosphamide, and peripheral blood stem Table 4 for results of multivariate analysis].
CD outcomes
Mortality and complications
One patient died at Day +56 post-AHSCT due to CMV infection, sepsis, and multiorgan failure, i.e. a transplant-related mortality of 1.2%. Another patient died at 7.99 years post-AHSCT from sepsis and multi-organ failure. In the year post-AHSCT, 22 At latest follow-up, 42/78 patients [54%] were on treatment.
In patients who had re-initiated medical therapy at latest followup, 24/42 [57%] achieved remission or significant symptomatic improvement with therapies (including anti-tumour necrosis factor [TNF] therapy in 19/24) to which they had previously lost response or been non-responsive.
Discussion
The principal finding of this retrospective survey using the EBMT registry is that AHSCT in patients with severe, treatment-refractory CD can induce complete remission or significant improvement in around two-thirds [68%] at long-term follow-up; 55% were alive and off all treatment at 1 year. In a multivariate analysis, extensive disease with perianal disease was associated with adverse treatmentfree survival. This is in keeping with the results of ASTIC, which demonstrated that patients with perianal disease or current smokers had a higher incidence of complications following AHSCT. 20 As such, patients with perianal disease should be considered to be at higher risk of complications and relapse requiring re-initiation of treatment. An appreciable minority of 27% remained off all therapy until latest follow-up, and 57% of patients who recommenced medical therapy following AHSCT were re-sensitised to therapies to which they had previously been refractory.
Although AHSCT alone does not frequently result in cure or long-term remission, it appears to have profound benefit in this highly refractory and difficult to treat patient population, where disease control and associated quality of life are poor, and life expectancy is reduced. Of note, chronic active CD treated with intense immunosuppressive regimens in the absence of AHSCT is also associated with significant morbidity and increased mortality. 21 This is the largest cohort of patients undergoing AHSCT for CD reported to date, and adds significantly to the evidence supporting its efficacy.
A further important finding of this study is that the safety of AHSCT in this population is similar to AHSCT for other common indications, such as myeloma and lymphoma, reflected by a transplant-related mortality of 1.2%. 7 There was one transplant-related death in our cohort, and a second patient died at 7.99 years; 28% developed an infection post-transplant, in keeping with transplantassociated infective complications in other diseases. The three cases of skin cancer observed may be linked to the longstanding multiagent immunosuppression experienced by this patient cohort. Optimising supportive care and restricting AHSCT to experienced centres has been shown to help mitigate AHSCT risk. 22, 23 In accordance with the Joint Accreditation Committee-ISCT and EBMT [JACIE] requirements, all AHSCT procedures in Europe are reported to the EBMT registry. The majority of patients in this study were treated following the 2012 EBMT Guidelines, which formed the basis for patient selection and transplant technique. 6 Through pan-European multicentre collaboration, we were able to obtain patient-level data, including long-term follow-up. As a retrospective evaluation, however, our study has intrinsic limitations. First, evaluation of clinical response was performed retrospectively. However, to reduce the risk of recall bias, contemporaneous notes were reviewed in all cases. To ensure accurate information, data collection was performed by the patient's treating gastroenterologist. Second, the categorisation of clinical response was necessarily broad, which is unlikely to fully reflect the spectrum of clinical disease response. We elected not to collect imaging, endoscopic, or biomarker outcomes, as these investigations were not performed in a systematic manner for all patients. Finally, data were not available on quality of life outcomes. Outcomes from a subset of 19 patients in this cohort have been previously reported in a single-centre study. 17 ASTIC is the only randomised controlled trial of AHSCT for CD to date. 19 The 1-year follow-up data of 40 transplant recipients in ASTIC provide further evidence of efficacy, with complete endoscopic healing occurring in 50% of patients, and 47% were judged free of disease on endoscopy and imaging at 1 year. 20 There was also a significant improvement from baseline to 1 year after transplant across multiple clinical, quality of life, and endoscopic endpoints. Those who did relapse were re-sensitised to TNF therapy to which they had previously been refractory, as in our study. 20 Single-centre studies with longer-term follow-up have reported that AHSCT does not offer indefinite remission and, as in our study, high rates of restarting medical therapy are observed. 10, 17 However, CD appears to be more responsive to therapy after AHSCT even where a clinical relapse occurs. Against this background, our findings lend support to a strategy of AHSCT with re-introduction of drug therapy to enable longer-term remissions in this complex patient cohort.
Recently, ECCO and EBMT have produced a collaborative update and review of the field, offering specific guidance on the clinical role of AHSCT and how it should be delivered. 24 We propose that future CD patients undergoing AHSCT outside clinical trials are enrolled in a European registry study to ensure harmonisation of outcome assessment. Although our data suggest a complication rate similar to other indications for AHSCT, it must be recognised that AHSCT represents an intensive therapy with significantly higher short-term risks than conventional treatments for CD. Late effects are a risk both for AHSCT and more conventional immunosuppressive therapies, due to the cumulative burden of many intense lines of treatment in these complex patients, which even in the absence of AHSCT is associated with significant morbidity and increased mortality. 21 Such late effects are broad in spectrum, affect many organ systems, and require systematic evaluation. Our current study highlights some of the issues, for example the skin cancers and secondary autoimmune disease. 25 Longterm follow-up of patients combined with prospective data collection should help to evaluate these risks post-AHSCT.
The mechanism of action of AHSCT in CD remains ill-defined. AHSCT has been shown to drive profound changes to the innate and adaptive immune system. 7, 26 First, cytotoxic chemotherapy in combination with T cell depletion ablates autoreactive effector cells that may have been refractory to previous immunosuppressive and biologic therapies. Next, the immune system regenerates with thymic reactivation and diversification of the T cell receptor repertoire. New, tolerant regulatory T cells traffic and suppress re-emergent autoreactive T effector cells. A small pilot study provides some evidence that the immunomodulatory effects of AHSCT apply in CD, with an increase in Foxp3+ T regulatory cells and a reduction in cytokinesecreting effector cells. 27 In CD, there may be additional effects from mobilisation and induction chemotherapy on the gastrointestinal mucosa, changes to the microbiome, and effects from G-CSF and antibiotics. It is likely that a combination of these factors underlies the disease response and regain of responsiveness to agents to which patients were previously refractory.
In conclusion, this study supports the safety and efficacy of AHSCT in patients with severe CD, yielding long-term clinical remissions in a patient cohort refractory to existing medical therapy. Important questions remain. These include defining parameters for selection of the patient subgroup most likely to respond to AHSCT, whether reducedintensity conditioning regimens could improve safety and reduce toxicity, and whether the effect of AHSCT can be optimised with early introduction of post-AHSCT maintenance therapy. Optimising supportive care and restricting AHSCT to experienced centres is likely to help mitigate AHSCT risk. 22 Additionally, greater insight into the mechanisms by which AHSCT induces self-tolerance may open the door to novel targeted therapies. Further randomised clinical studies are warranted to assess the role of AHSCT in this challenging disease.
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